Sichuan Jinjiang Electronic Medical Device Technology Co. Ltd. received approval from China’s National Medical Products Administration (NMPA) approval for the commercial use of its PFA technology in the treatment of atrial fibrillation, making it the first pulsed field ablation device to gain approval in the country.
Medtronic plc made history with the first U.S. FDA approval of pulsed field ablation for paroxysmal and persistent atrial fibrillation in the U.S., giving the company a significant first-mover advantage in a field that is expected to cannibalize the cardiac ablation market.
